Cargando…

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research

BACKGROUND: Despite the introduction of novel effective treatment regimens like gemcitabine plus nab-paclitaxel and FOLFIRINOX, pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive epithelial tumors. Among the genetic alterations frequently found in PDAC, mutations in the KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baechmann, Sibylle, Ormanns, Steffen, Haas, Michael, Kruger, Stephan, Remold, Anna, Modest, Dominik Paul, Kirchner, Thomas, Jung, Andreas, Werner, Jens, Heinemann, Volker, Boeck, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445280/ https://www.ncbi.nlm.nih.gov/pubmed/28549417 http://dx.doi.org/10.1186/s12885-017-3376-4

Ejemplares similares

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
por: Ormanns, Steffen, et al.
Publicado: (2016)

The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy
por: Ormanns, Steffen, et al.
Publicado: (2017)

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer
por: Haas, Michael, et al.
Publicado: (2017)

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2020)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult
por: Boeck, S, et al.
Publicado: (2014)

TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
por: Guenther, Michael, et al.
Publicado: (2023)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
por: Ormanns, Steffen, et al.
Publicado: (2014)

Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers
por: Dorman, Klara, et al.
Publicado: (2022)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer
por: Guenther, Michael, et al.
Publicado: (2022)

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Sams, L., et al.
Publicado: (2021)

Advances in cancer immunotherapy 2019 – latest trends
por: Kruger, Stephan, et al.
Publicado: (2019)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

Epithelial-Mesenchymal Transition Induces Endoplasmic-Reticulum-Stress Response in Human Colorectal Tumor Cells
por: Zeindl-Eberhart, Evelyn, et al.
Publicado: (2014)

WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear β-Catenin depend on active PI3K signaling
por: Ormanns, Steffen, et al.
Publicado: (2014)

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
por: Kruger, S.F., et al.
Publicado: (2022)

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
por: Reinacher-Schick, Anke, et al.
Publicado: (2012)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Mutations in the WTX - gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers
por: Scheel, Silvio K, et al.
Publicado: (2010)

ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis
por: Wang, Lidong, et al.
Publicado: (2015)

KRAS is vulnerable to reversible switch-II pocket engagement in cells
por: Vasta, James D., et al.
Publicado: (2022)

Probing the KRas Switch II Groove by Fluorine NMR Spectroscopy
por: Peacock, D. Matthew, et al.
Publicado: (2022)

Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
por: Strickler, John H, et al.
Publicado: (2023)

A Novel KRAS Antibody Highlights a Regulation Mechanism of Post-Translational Modifications of KRAS during Tumorigenesis
por: Assi, Mohamad, et al.
Publicado: (2020)

Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting
por: Sultova, Elena, et al.
Publicado: (2021)

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer
por: Aguilera, Oscar, et al.
Publicado: (2016)

Unusual Course of Lafora Disease
por: Zutt, Rodi, et al.
Publicado: (2016)

NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU
por: Sultova, Elena, et al.
Publicado: (2020)

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS(G12C) Inhibitor
por: Bröker, Joachim, et al.
Publicado: (2022)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS
por: Kalvala, Arjun, et al.
Publicado: (2019)

Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
por: Mahajan, Ujjwal M, et al.
Publicado: (2019)

An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course
por: Kohutek, Zachary A., et al.
Publicado: (2017)

An Unusual Course of Metastatic Gastroesophageal Cancer
por: Smith, William H., et al.
Publicado: (2015)

The unusual angiographic course of intracranial pseudoaneurysms
por: Zanaty, Mario, et al.
Publicado: (2015)

Strangulated Hernia with an Unusual History and Course
por: Gorur, S. R.
Publicado: (1943)

Unusual course of a haematoma of the thigh
por: Ourique, Carolina, et al.
Publicado: (2017)

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE ‐ hypermutated colorectal cancers
por: Favre, Loetitia, et al.
Publicado: (2022)

ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation
por: Jia, Daqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v5u3eofirdmo4121e110qgfs85